Abstract
The global response to finding therapeutics for coronavirus disease 2019 (COVID-19) is chaotic even if well intentioned. There is an opportunity, but more importantly, an obligation for the global clinical and quantitative pharmacology community to come together and use our state-of-the-art tools and expertise to help society accelerate therapeutics to fight COVID-19. This brief commentary is a call to action and highlights how the global pharmacology community should contribute to the COVID-19 pandemic and prepare for future pandemics.
© 2020 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antiviral Agents / adverse effects
-
Antiviral Agents / pharmacokinetics
-
Antiviral Agents / therapeutic use*
-
Betacoronavirus / drug effects*
-
Betacoronavirus / pathogenicity
-
COVID-19
-
Coronavirus Infections / diagnosis
-
Coronavirus Infections / drug therapy*
-
Coronavirus Infections / virology
-
Dose-Response Relationship, Drug
-
Drug Approval / organization & administration*
-
Drug Development / organization & administration*
-
Drug Discovery / organization & administration*
-
Drug Dosage Calculations
-
Humans
-
Pandemics
-
Patient Safety
-
Pharmacology, Clinical / organization & administration*
-
Pneumonia, Viral / diagnosis
-
Pneumonia, Viral / drug therapy*
-
Pneumonia, Viral / virology
-
SARS-CoV-2
-
Time Factors
-
Workflow